共查询到20条相似文献，搜索用时 156 毫秒
1.
按凝血过程激发、放大、凝血酶和纤维蛋白形成的顺序，从原理、临床试验、到作为抗栓塞新药应用对目前国内外抗凝血药物的研究进行了详细评述． 相似文献
2.
冬青属（Ilex）植物树皮浸出液凝血功能的研证 总被引：1，自引：0，他引：1
冬青属(Ilex)植物在我国民间防治疾病，具有悠久历史，多用于清热解毒、消炎、镇咳、止病等。本文将冬青属(Ilex)植物的树皮浸出液用于凝血试验，结果表明：1．某些冬青属植物树皮内含物质具有凝血作用；2．冬青属植物树皮白酒(50&;#176;)浸出液不同浓度凝血速度不同，选用冬青属植物树皮浓度为0．125g／ml，乙醇含量为12．5％的浸出液凝血效果显著。 相似文献
3.
血栓形成机理涉及血管壁损伤、血小板聚集、血液凝固性增加和血液流变学异常.凝血、纤溶变化的检测在静脉血栓性静脉炎的治疗中有重要意义.本实验旨在从改善血液高凝状态及促纤溶作用方面探讨血栓康抑制静脉血栓形成及血栓性静脉炎的作用机制,为临床提供理论和实验依据. 相似文献
4.
大活络丸的活血化瘀作用 总被引：1，自引：0，他引：1
经NIH小鼠灌胃实验,大活络丸的最大耐受量为27.2g/kg,按最大耐受量1/40,1/20,1/10设置药效学实验3个剂量组.大活络丸对小鼠热板法致痛具显著镇痛作用,扩张兔耳外周血管,增加兔耳灌流量,缓解血栓形成,延长凝血时间,有显著活血化瘀作用. 相似文献
5.
从麻黄果中提取的多糖成分,使体外凝血时间、凝血活酶时间和白陶土部分凝血活酶时间均较正常对照组延长(P<0.01).说明麻黄果中多糖成分可以通过内外源凝血两条途径影响血液凝固过程。 相似文献
6.
7.
一种测定凝血酶抑制剂活性的新方法 总被引：2，自引：0，他引：2
赵荣乐 《喀什师范学院学报》2003,24(6):52-55
报告了一种新的测定凝血酶抑制剂抑制活性的测定方法——发色底物吸光值变化率法；以发色底物S-2238与标准凝血酶反应测定未抑制吸光值变化率，同时以发色底物S-2238与凝血酶抑制剂和标准凝血酶反应测定抑制吸光值变化率，然后以抑制吸光值变化率与未抑制吸光值变化率的比值计算凝血酶抑制剂的抑制活性．实验证明，这种凝血酶抑制剂抑制活性测定方法简便易行，重复性高，偶然误差小，可信度大。 相似文献
8.
低分子肝素是由普通肝素经硝酸去极化分解、纯化所得低分子氨基葡聚糖的钙盐 ,其平均分子量约为4 5 0 0ｕ[1] 。由于其具有抗凝血、抗血栓的药理作用 ,临床上用于防治深部静脉血栓、肺栓塞、播散性血管内凝血等疾病。现就其在不稳定型心绞痛、急性冠脉综合征、急性脑梗死方面的应用作一综述。1 治疗不稳定型心绞痛不稳定型心绞痛是一种介于稳定型心绞痛和急性心肌梗死之间的临床状态 ,病情较重 ,预后较差。主要由于冠状动脉粥样硬化逐渐加重致斑块破裂、出血、血栓形成 ,不稳定型心绞痛患者冠状动脉腔内血栓形成发生率约为 80 %～ 90 % [2 … 相似文献
9.
血小板在止血、凝血、血栓形成及保持血管壁完整性方面起着重要作用。骨髓巨核细胞将成熟的血小板释放到血循环中,随着血小板的成熟及老化,其功能逐渐减退,继而丧失。血小板在未梢血中平均寿命为10～14天,因此必然存在幼稚、成熟及衰老等各阶段,在形态学方面计数血小板各阶段的比率,有助于临床诊断参考。将血小板悬液载 相似文献
10.
11.
采用聚合硫酸铝铁(PFSA)对城市污水处理厂生化出水混凝除磷,考察PFSA投加量对磷和出水pH的影响,污水pH、沉淀时间对混凝除磷效果的影响.同时进行了聚合硫酸铁(PFS)、硫酸铝的混凝除磷比较实验.结果表明,聚合硫酸铁铝(PFSA)具有对出水pH的影响较小,对磷去除率高,pH值适用范围宽的优势.PFSA在投加量为6.0mL/L时,沉淀时间为40min时,出水磷0.24mg/L,磷去除率可以达到84%,出水满足辽宁省污水综合排放标准(DB2008). 相似文献
12.
Ruszkowska B Gadomska G Bielis L Gruszka M Góralczyk B Rość D Odrowąż-Sypniewska G 《Journal of Zhejiang University. Science. B》2011,12(1):12-17
Objective
The influence of hormone replacement therapy (HRT) on hemostasis processes depends on the type of hormone, the combination of doses, the time of taking HRT, and the route of administration (oral, transdermal, implanted). The aim of the current study was to assess some parameters of coagulation, especially tissue factor pathway inhibitor (TFPI) and tissue factor (TF) in postmenopausal women using oral or transdermal HRT. 相似文献13.
INTRODUCTIONCoronaryarterydisease (CAD)continuestobethemajorcauseofmorbidityandmortalityinourcountry .TheactivityofbloodcoagulationfactorshasbeenshowntobeanimportantriskindicatorforCAD .However,circulatinglevelsofcoagulationfactorsmaynotaccuratelyreflectt… 相似文献
14.
Objective: To determine whether polymorphisms in the genes for coagulation factor. II, V, VII could predispose an individual
to increase risk for coronary artery disease (CAD) and/or myocardial infarction (MI) in Chinese. Methods: We screened coagulation
factor II(G20210A), V(G1691A), VII (R353Q and HVR4) genotype in 374 patients undergoing coronary angiography by polymerase
chain reaction and restriction fragment length polymorphism (PCR-RFLP) assay. Results: The R353Q and HVR4 gemotype of the
factor VII distribution was in accordance with Hardy-Weinberg equilibrium. The frequencies of FVII genotype or allele did
not show statistically significant differences between CAD group and controls or between male and female. The frequencies
of the Q allele and (RQ+QQ) genotype were significantly higher among the CAD patients without myocardial infarction (MI) history
than among those with MI history (P<0.05). However, HVR4 polymorphism was not significantly different within groups. We only find one normal control of factorII
(G20210A) mutation. No coagulation factor V(G1691A) mutation was found in the CAD patients and controls. Conclusion: The factor
II(G20210A), V(G1691A) mutation is absent and may not be a major genetic factor for CAD and/or MI; the Q allele of the R353
Q polymorphism of the factor VII gene may be a protective genetic factor against myocardial infarction in Chinese.
Project (No. 021103166) supported by a grant from the Key Project of Science and Technology Commission of Zhejiang Province,
China 相似文献
15.
In order to remove the low turbidity present in surface water, a novel metal-polysilicate coagulant was used to treat the raw water taken from Tanjiang River in Guangdong Province. This study on the effects of Al/Fe molar ratio on the performance of a complex compound formed by polysilicic acid, aluminium and ferric salt (PAFS) showed that PAFS with Al/Fe ratio of 10:3 seemed to have the best coagulation performance in removing turbidity and color. Experimental results showed that under the conditions of polymerization time of 15 d, sedimentation time of 12 min, and pH of 6(8, PAFS with Al/Fe molar ratio of 10:3 had the best coagulation efficiency and lowest residual Al concentration. The turbidity decreased from 23.8 NTU to 3.23 NTU and the residual Al concentration was only 0.165 mg/L in the product water. It could be speculated that colloidal impurities and particulate Al were removed by adsorption bridging and electrical neutralization of long chain inorganic polymer coagulants. 相似文献
16.
Study on coagulation property of metal-polysilicate coagulants in low turbidity water treatment 总被引：2，自引：0，他引：2
INTRODUCTION Coagulation-flocculation is a major step inthe potable water treatment for removal of colloi-dal impurity. Due to the increase of water pollu-tion, the standards of drinking water supply andwastewater discharge are becoming more and morestringent, and chemical coagulants that are moreefficient in water treatment are more and moreurgently in demand. As well known, the residual Al in potablewater comes from three main sources: natural wa-ter-body, coagulants used in… 相似文献
17.
18.
Xiao-jie Xie Ju-bo Jiang Jun Jiang Jian-an Wang 《Journal of Zhejiang University. Science. B》2014,15(9):838-844
Based on different mechanisms of blood coagulation, coexistence of venous thromboembolism and arterial thrombosis in a single individual is extremely rare in clinical practice. Both antiplatelet and anticoagulation therapy should be adopted for patients with arteriovenous embolism. Balancing the risk of ischemia and hemorrhage is especially challenging in these patients in order to achieve an optimal clinical benefit. We report on a 55-year-old female with acute pulmonary embolism (PE), subsequently diagnosed as having acute myocardial infarction (AMI) and a cerebral infarction. Examinations had been carried out, excluding potential arteriovenous shunts, cancer, antiphospholipid syndrome and other common hypercoagulable states. A combination of an anticoagulant drug (rivaroxaban, an Xa inhibitor) and an antiplatelet agent (clopidogrel, an ADP receptor inhibitor) was prescribed with a β-blocker and atorvastatin. The embolus was gradually shrunk during the next 10 months, and then it turned back into expanding. During the 16 months’ follow-up, an aneurysm of left ventricular apex was found through an echocardiogram and an angiotensin-converting enzyme inhibitor was administered. We conclude that combined anticoagulation and antiplatelet therapy significantly relieved the symptoms and improved the prognosis in patients suffering from arteriovenous embolism without any major clinical bleeding events. 相似文献
19.
褐藻多糖硫酸酯影响血小板聚集及血栓形成 总被引：18，自引：0，他引：18
研究褐藻多糖硫酸酯对实验性出血、血栓形成及血小板聚集的影响 ;比较褐藻多糖硫酸酯给药后动物实验性出血时间及出血量的变化 ,比较褐藻多糖硫酸酯给药后动物实验性动、静脉血栓形成的变化 ,血小板聚集仪测定褐藻多糖硫酸酯对AA、ADP、CaCl2 、凝血酶诱导的血小板聚集的影响 ;褐藻多糖硫酸酯能够延长动物实验性出血时间并增加出血量 ,能够抑制动物实验性动、静脉血栓的形成 ,能够抑制体外诱导的血小板聚集 ;褐藻多糖硫酸酯对血栓形成具有抑制作用 ,该作用可能与抑制血小板聚集有关。 相似文献
20.
研究混凝———高效复合微生物对于煤气洗涤废水的处理效果 试验表明 ,采用HC型混凝剂进行混凝沉淀预处理和高效复合微生物氧化法二段工艺 ,可使隔油池后的煤气洗涤废水处理达到行业排放标准 相似文献